IONIS PHARMACEUTICALS INC

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

IONS$28.19-9.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity

Common Stock · Additional · Accumulated Other · Accumulated · Total Stockholders’
Description	Shares	Amount	Paid in Capital	Comprehensive Loss	Deficit	Equity
Balance at June 30, 2023	143,167	$143	$2,118,309	$(50,913)	$(1,639,238)	$428,301
Net loss	—	—	—	—	(147,410)	(147,410)
Change in unrealized gains, net of tax	—	—	—	5,029	—	5,029
Foreign currency translation	—	—	—	(153)	—	(153)
Issuance of common stock in connection with employee stock plans, net	226	—	3,729	—	—	3,729
Stock-based compensation expense	—	—	25,964	—	—	25,964
Balance at September 30, 2023	143,393	$143	$2,148,002	$(46,037)	$(1,786,648)	$315,460
Balance at June 30, 2024	146,025	$146	$2,303,369	$(34,838)	$(2,004,979)	$263,698
Net loss	—	—	—	—	(140,480)	(140,480)
Change in unrealized gains, net of tax	—	—	—	10,315	—	10,315
Foreign currency translation	—	—	—	350	—	350
Issuance of common stock in connection with employee stock plans, net	288	—	7,002	—	—	7,002
Issuance of public common stock, net	11,500	12	489,081	—	—	489,093
Stock-based compensation expense	—	—	32,490	—	—	32,490
Balance at September 30, 2024	157,813	$158	$2,831,942	$(24,173)	$(2,145,459)	$662,468

Index

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

Common Stock · Additional · Accumulated Other · Accumulated · Total Stockholders’
Description	Shares	Amount	Paid in Capital	Comprehensive Loss	Deficit	Equity
Balance at December 31, 2022	142,058	$142	$2,059,850	$(57,480)	$(1,429,625)	$572,887
Net loss	—	—	—	—	(357,023)	(357,023)
Change in unrealized gains, net of tax	—	—	—	11,421	—	11,421
Foreign currency translation	—	—	—	22	—	22
Issuance of common stock in connection with employee stock plans, net	1,335	1	8,679	—	—	8,680
Stock-based compensation expense	—	—	79,473	—	—	79,473
Balance at September 30, 2023	143,393	$143	$2,148,002	$(46,037)	$(1,786,648)	$315,460
Balance at December 31, 2023	144,341	$144	$2,215,098	$(32,645)	$(1,795,911)	$386,686
Net loss	—	—	—	—	(349,548)	(349,548)
Change in unrealized gains, net of tax	—	—	—	8,259	—	8,259
Foreign currency translation	—	—	—	213	—	213
Issuance of common stock in connection with employee stock plans, net	1,972	2	33,205	—	—	33,207
Issuance of public common stock, net	11,500	12	489,081	—	—	489,093
Stock-based compensation expense	—	—	94,558	—	—	94,558
Balance at September 30, 2024	157,813	$158	$2,831,942	$(24,173)	$(2,145,459)	$662,468

Index

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.